Nilotinib Zentiva (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, a fusion protein that drives CML cell proliferation. By blocking this enzyme, the drug halts downstream signaling pathways, leading to reduced growth of leukemic cells and promoting apoptosis, especially in cells harboring BCR‑ABL mutations.

The specific dose of Nilotinib Zentiva is determined by the prescribing physician based on the individual’s disease status, prior therapy, and overall health. Dosing recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.

Nilotinib is classified as pregnancy category unknown, and there are no adequate studies confirming safety in pregnant or nursing women. Consequently, it is generally avoided during pregnancy and lactation, and effective contraception is recommended for women of child‑bearing potential while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nilotinib Zentiva. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to Nilotinib is imatinib, another BCR‑ABL tyrosine kinase inhibitor. Nilotinib has higher potency against many BCR‑ABL mutations and may be effective when imatinib resistance occurs. However, Nilotinib is associated with a distinct safety profile, including a higher risk of cardiovascular events, which clinicians must weigh against its efficacy benefits.

Nilotinib Zentiva tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Nilotinib Zentiva is taken orally, usually twice daily on an empty stomach—at least one hour before or two hours after a meal. The tablets should be swallowed whole with a glass of water and not crushed or chewed. Patients should follow the exact timing and dietary instructions provided by their prescriber.

The most serious risks include cardiovascular events such as arterial occlusive disease, myocardial infarction, or stroke; severe liver toxicity indicated by marked elevations in transaminases; and pancreatitis. Patients should be monitored regularly for cardiac symptoms, liver function abnormalities, and signs of pancreatic inflammation, and they should seek immediate medical attention if these occur.

Nilotinib should not be used by individuals with known hypersensitivity to nilotinib or any of its excipients. It is also contraindicated in patients with a history of prolonged QT interval or uncontrolled cardiac arrhythmias, and it should be avoided in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.